{"id":31264,"date":"2025-09-01T19:59:44","date_gmt":"2025-09-01T19:59:44","guid":{"rendered":"https:\/\/www.hotelsalepage.com\/feed\/cision-pr-newswire\/ami-pharms-ayp-101-shows-promise-in-phase-2-trial-signaling-a-breakthrough-in-nonsurgical-fat-reduction\/"},"modified":"2025-09-01T19:59:44","modified_gmt":"2025-09-01T19:59:44","slug":"ami-pharms-ayp-101-shows-promise-in-phase-2-trial-signaling-a-breakthrough-in-nonsurgical-fat-reduction","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=31264","title":{"rendered":"AMI Pharm&#8217;s AYP-101 Shows Promise in Phase 2 Trial, Signaling a Breakthrough in Nonsurgical Fat Reduction"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2744184\/AMI_Pharm_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li>AMI Pharm&#8217;s &#8216;AYP-101&#8217; Sets to Become a New Leader in Nonsurgical Fat Reduction with Phase 2 Trial Success<\/li>\n<li>&#8216;AYP-101,&#8217; a Promising Nonsurgical Solution, Has Its Clinical Results Published in Clinical Therapeutics<\/li>\n<li>&#8216;AYP-101&#8217; Demonstrates Superior Safety and Efficacy, Poised to Change the Paradigm of Submental Fat Reduction<\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SEOUL, South Korea<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Sept. 1, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0<a href=\"http:\/\/www.amipharm.com\/en\/index.php\" target=\"_blank\" rel=\"nofollow\">AMI Pharm<\/a>&#8216;s novel injectable drug, AYP-101, has shown promising results in a Phase 2 clinical trial for the reduction of submental fat (SMF), commonly known as a double chin. The clinical data from the trial was recently published in <i>Clinical Therapeutics<\/i>, a leading journal for drug and therapy development. This publication marks a significant milestone for AYP-101 and highlights its potential as a safe and effective nonsurgical treatment option. The study evaluated the efficacy and safety of AYP-101 at two different concentrations. The results showed that the 25 mg\/mL concentration, administered every two weeks for six sessions, led to statistically significant and clinically meaningful reductions in moderate to severe SMF.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p><b>Demonstrated Efficacy and Safety<\/b><\/p>\n<p>The Phase 2 study enrolled 96 participants and demonstrated strong results. At four weeks after the final treatment, 69.70% of participants in the 25 mg\/mL treatment group achieved at least a one-grade improvement in both the Evaluator-Reported and Subject-Reported Submental Fat Rating Scales (ER-SMFRS and SR-SMFRS). This was a statistically significant improvement compared to the 22.58% response rate in the placebo group. The trial data also highlighted AYP-101&#8217;s favorable safety and tolerability profile. The drug is uniquely designed to eliminate fat through a process called apoptosis while minimizing damage to surrounding tissues. The study found that AYP-101 required fewer injection points and produced a lower incidence of post-injection swelling and paresthesia compared to what is typically reported for Deoxycholic Acid (DCA).<\/p>\n<p><b>A Leader in the Growing Aesthetics Market<\/b><\/p>\n<p>With the global demand for nonsurgical fat reduction solutions on the rise, AMI Pharm is actively pursuing the next phase of development. According to Ki-Taek Lee, CEO of AMI Pharm, the publication of the Phase 2 data &#8220;reaffirms our research capabilities and demonstrates AYP-101&#8217;s significant potential in the localized fat reduction market&#8221;. AMI Pharm is currently accelerating its Phase 3 study for AYP-101 with the goal of completion by the end of 2025. The company is also actively expanding international collaborations to further develop next-generation injectable drugs for localized fat reduction. This latest publication follows the positive results from AYP-101&#8217;s Phase 1 study in 2024, continuing its international recognition.<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2744184\/AMI_Pharm_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li>AMI Pharm&#8217;s &#8216;AYP-101&#8217; Sets to Become a New Leader in Nonsurgical Fat Reduction with Phase 2 Trial Success<\/li>\n<li>&#8216;AYP-101,&#8217; a Promising Nonsurgical Solution, Has Its Clinical Results Published in Clinical Therapeutics<\/li>\n<li>&#8216;AYP-101&#8217; Demonstrates Superior Safety and Efficacy, Poised to Change the Paradigm of Submental Fat Reduction<\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SEOUL, South Korea<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Sept. 1, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0<a href=\"http:\/\/www.amipharm.com\/en\/index.php\" target=\"_blank\" rel=\"nofollow\">AMI Pharm<\/a>&#8216;s novel injectable drug, AYP-101, has shown promising results in a Phase 2 clinical trial for the reduction of submental fat (SMF), commonly known as a double chin. The clinical data from the trial was recently published in <i>Clinical Therapeutics<\/i>, a leading journal for drug and therapy development. This publication marks a significant milestone for AYP-101 and highlights its potential as a safe and effective nonsurgical treatment option. The study evaluated the efficacy and safety of AYP-101 at two different concentrations. The results showed that the 25 mg\/mL concentration, administered every two weeks for six sessions, led to statistically significant and clinically meaningful reductions in moderate to severe SMF.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p><b>Demonstrated Efficacy and Safety<\/b><\/p>\n<p>The Phase 2 study enrolled 96 participants and demonstrated strong results. At four weeks after the final treatment, 69.70% of participants in the 25 mg\/mL treatment group achieved at least a one-grade improvement in both the Evaluator-Reported and Subject-Reported Submental Fat Rating Scales (ER-SMFRS and SR-SMFRS). This was a statistically significant improvement compared to the 22.58% response rate in the placebo group. The trial data also highlighted AYP-101&#8217;s favorable safety and tolerability profile. The drug is uniquely designed to eliminate fat through a process called apoptosis while minimizing damage to surrounding tissues. The study found that AYP-101 required fewer injection points and produced a lower incidence of post-injection swelling and paresthesia compared to what is typically reported for Deoxycholic Acid (DCA).<\/p>\n<p><b>A Leader in the Growing Aesthetics Market<\/b><\/p>\n<p>With the global demand for nonsurgical fat reduction solutions on the rise, AMI Pharm is actively pursuing the next phase of development. According to Ki-Taek Lee, CEO of AMI Pharm, the publication of the Phase 2 data &#8220;reaffirms our research capabilities and demonstrates AYP-101&#8217;s significant potential in the localized fat reduction market&#8221;. AMI Pharm is currently accelerating its Phase 3 study for AYP-101 with the goal of completion by the end of 2025. The company is also actively expanding international collaborations to further develop next-generation injectable drugs for localized fat reduction. This latest publication follows the positive results from AYP-101&#8217;s Phase 1 study in 2024, continuing its international recognition.<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-31264","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/31264","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31264"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/31264\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31264"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31264"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31264"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}